Elicio Therapeutics ( (ELTX) ) has issued an announcement.
On March 21, 2025, Elicio Therapeutics appointed Preetam Shah, Ph.D., M.B.A., as Chief Strategy and Financial Officer, effective March 24, 2025. Dr. Shah’s extensive experience in corporate finance and strategy is expected to be a significant asset as Elicio advances its immunotherapy platform and prepares for key clinical milestones. His appointment comes at a crucial time for the company, which is focusing on the development of its lead product candidate, ELI-002, and other cancer vaccines. This strategic leadership change is anticipated to bolster Elicio’s efforts in aligning financial and corporate strategies with its goal of delivering cutting-edge cancer immunotherapeutics.
More about Elicio Therapeutics
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, such as mKRAS-positive pancreatic and colorectal cancers. The company leverages its proprietary Amphiphile platform to enhance cancer-specific T cell responses and aims to provide off-the-shelf vaccines like ELI-002, targeting common KRAS mutations.
YTD Price Performance: 70.23%
Average Trading Volume: 44,350
Technical Sentiment Signal: Sell
Current Market Cap: $138.8M
For detailed information about ELTX stock, go to TipRanks’ Stock Analysis page.